文献速递放疗物理与技术姑息放疗与转移瘤

空间分割放射治疗的实践模式:一项临床实践调查

Practice Patterns of Spatially Fractionated Radiation Therapy: A Clinical Practice Survey.
PubMed 文献 · Adv Radiat Oncol · 2023-07-09

本研究通过问卷调查评估放射肿瘤科医生在空间分割放射治疗(SFRT)中的患者选择、剂量规划、剂量学参数使用、技术平台及联合常规外照射(cERT)和多模式治疗的模式。多数医生将SFRT视为大体积/晚期肿瘤的可接受标准治疗选项,但SFRT与cERT的联合时序及剂量学参数的临床应用存在差异。

要点

  • 美国100%、全球72.7%的执业放射肿瘤科医生认为SFRT是大体积/晚期肿瘤可接受的标准治疗选项。
  • 姑息性SFRT以15至18 Gy/1次方案为主(51.3%),根治性非转移肿瘤以15 Gy/1次(28.0%)和分次SFRT(24.0%)最常见。
  • LRT较GRID更常用SFRT异质性剂量学参数(P = .008),且更常认为其影响局部控制(峰值剂量,P = .008)。

核心结论

  • SFRT已演变为晚期/大体积肿瘤的临床实践模式,主要治疗方法一致且遵循文献,但SFRT-cERT联合时序及剂量学参数的临床应用存在差异。

研究设计与样本

  • 一项旨在识别放射肿瘤科医生SFRT实践模式的问卷调查,数据用描述性统计总结,组间比较采用置换检验。

主要发现

  • 美国100%、全球72.7%的执业放射肿瘤科医生认为SFRT是大体积/晚期肿瘤可接受的标准治疗选项。
  • 常见治疗转移/复发和非转移原发肿瘤,主要为头颈、肺癌和肉瘤。
  • 姑息性SFRT以15至18 Gy/1次方案为主(51.3%),根治性非转移肿瘤以15 Gy/1次(28.0%)和分次SFRT(24.0%)最常见。
  • SFRT常与cERT联合但并非总是联合,姑息治疗中占78.6%,根治性治疗中占85.7%;SFRT-cERT时间顺序和cERT剂量调整存在差异。
  • 根治性治疗中,同步化疗和免疫治疗分别被54.5%和28.6%的医生认为可接受。

关键数值与推荐

  • 姑息性SFRT方案15至18 Gy/1次占51.3%。
  • 根治性非转移肿瘤中15 Gy/1次占28.0%,分次SFRT占24.0%。
  • SFRT与cERT联合在姑息治疗中占78.6%,根治性治疗中占85.7%。
  • 根治性治疗中同步化疗可接受比例54.5%,同步免疫治疗可接受比例28.6%。
  • LRT较GRID更常用SFRT异质性剂量学参数(P = .008),更常认为峰值剂量影响局部控制(P = .008)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Spatially fractionated radiation therapy (SFRT) is increasingly used for bulky advanced tumors, but specifics of clinical SFRT practice remain elusive. This study aimed to determine practice patterns of GRID and Lattice radiation therapy (LRT)-based SFRT. METHODS AND MATERIALS: A survey was designed to identify radiation oncologists' practice patterns of patient selection for SFRT, dosing/planning, dosimetric parameter use, SFRT platforms/techniques, combinations of SFRT with conventional external beam radiation therapy (cERT) and multimodality therapies, and physicists' technical implementation, delivery, and quality procedures. Data were summarized using descriptive statistics. Group comparisons were analyzed with permutation tests. RESULTS: The majority of practicing radiation oncologists (United States, 100%; global, 72.7%) considered SFRT an accepted standard-of-care radiation therapy option for bulky/advanced tumors. Treatment of metastases/recurrences and nonmetastatic primary tumors, predominantly head and neck, lung cancer and sarcoma, was commonly practiced. In palliative SFRT, regimens of 15 to 18 Gy/1 fraction predominated (51.3%), and in curative-intent treatment of nonmetastatic tumors, 15 Gy/1 fraction (28.0%) and fractionated SFRT (24.0%) were most common. SFRT was combined with cERT commonly but not always in palliative (78.6%) and curative-intent (85.7%) treatment. SFRT-cERT time sequencing and cERT dose adjustments were variable. In curative-intent treatment, concurrent chemotherapy and immunotherapy were found acceptable by 54.5% and 28.6%, respectively. Use of SFRT dosimetric parameters was highly variable and differed between GRID and LRT. SFRT heterogeneity dosimetric parameters were more commonly used (P = .008) and more commonly thought to influence local control (peak dose, P = .008) in LRT than in GRID therapy. CONCLUSIONS: SFRT has already evolved as a clinical practice pattern for advanced/bulky tumors. Major treatment approaches are consistent and follow the literature, but SFRT-cERT combination/sequencing and clinical utilization of dosimetric parameters are variable. These areas may benefit from targeted education and standardization, and knowledge gaps may be filled by incorporating identified inconsistencies into future clinical research.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Mayr NA, Mohiuddin M, Snider JW, et al. Practice Patterns of Spatially Fractionated Radiation Therapy: A Clinical Practice Survey. Adv Radiat Oncol. 2023. PMID: 38405319. doi:10.1016/j.adro.2023.101308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。